Sridhar Chaganti
@SridharChaganti
Followers
204
Following
68
Media
2
Statuses
32
Lymphoma and cell therapy Doc
Birmingham, England
Joined June 2017
RT @DrRaulCordoba: #Hematology Autologous stem cell transplantation for relapsed/refractory large B-cell #lymphoma: a multicenter @GETH_in….
ashpublications.org
Key PointsOur results indicate that ASCT is a curative option for patients with chemosensitive disease especially in CR after salvage.ASCT could still be c
0
12
0
RT @lymphomule: Waleed Alduaij at #icmlugano last week presented this well conducted retrospective study from British Columbia on double hi….
0
5
0
RT @ABarrettHaem: The incomparable @CwynKate sweeping a win for NO evidence for CNS prophylaxis at #ICML2025 !
0
6
0
A nice summary of the @BritSocHaem RR LBCL guideline in this thread by @lymphomule.
0
3
4
Just released BSH R/R LBCL guideline with updated guidance on this rapidly evolving field.
onlinelibrary.wiley.com
Time to progression is the strongest predictor of outcome in relapsed diffuse large B-cell lymphoma. Second-line treatment with chimeric antigen receptor (CAR) T-cell therapy is recommended for...
0
12
24
Great support for this clinical practice informing study from @CCH_Bham @uhbtrust @charliecraddock @nickduncan31 @UHBResearch and @UHBCharity.
0
0
0
👉 Comparable toxicity for OOS CAR T inf and controls.👍our data support OOS product infusion esp if viable CAR T cell dose within spec. 👎 Limitation: small sample size for some comparisons.
1
0
0
✅MF seen in 3.87%. 3.5% axicel and 5.7% tisacel.✅Prior bendamustine <6 months was the only risk factor for MF.✅ LBCL pts inf with OOS product have comparable outcomes to controls.✅Remanufacturing attempts led to delayed in-spec product inf in only around 50% of patients.
1
0
0
Out now in the @BloodCancerJnl. Our study on risk factors and outcomes of CAR T manufacturing failure (MF) in LBCL. Led by Vaishali Dulobdas on behalf of the UK national CAR T panel @tobiasmenne2 @maeveannoreilly @AnneBlackPharm @sghorashian @KuhnlAndrea.
nature.com
Blood Cancer Journal - Risk factors for CAR T-cell manufacturing failure and patient outcomes in large B-cell lymphoma: a report from the UK National CAR T Panel
1
4
17
Fantastic news and so richly deserved @nickduncan31.
Amazing news and well deserved @nickduncan31 !! Congratulations 🥳.
0
0
5
Featuring excellent set of speakers and topics frequently debated in mdts. Please register asap to access pre-recorded videos ahead of attending live webinar on 10th Oct. Suitable for all HCPs caring for lymphoma patients.
With pre-recorded videos available 🎉. & webinar chaired by #CathyBurton & @SridharChaganti . Places still available . @BritSocHaem.
0
1
5
RT @mattwilson2287: Just published in @BrJHaem - an updated @BritSocHaem good practice paper on the ever-controversial topic of CNS prophyl….
onlinelibrary.wiley.com
This Good Practice Paper provides recommendations for the baseline investigation, risk stratification and use of prophylactic interventions for patients with large B-cell lymphoma at risk of central...
0
35
0
Brilliant work by my colleague @lymphomule. Most MYC/BCL6r lymphomas harbour a single-hit, reciprocal translocation t(3;8) between MYC and BCL6 (pseudo double-hit) and have better outcomes than t(3;8) negative double-hit cases.
5
14
48
A fantastic collaborative effort from colleagues across the UK. Final results of the Tidal trial in newly diagnosed CD20+ PTLD are now online in Blood.
6
10
51
RT @BrJHaem: The management of newly diagnosed large B-cell lymphoma: A @BritSocHaem Guideline . (open access). @Dr….
0
39
0
RT @lymphomahub: CONGRESS #ASH23 | Vaishali Dulobdas, @uhbtrust presented a multicentre retrospective review of factors contributing to ma….
0
2
0
Fantastic presentation indeed!.
Excellent presentation by Vaishali o risk factors and outcomes of CAR T manufacturing failure. #ASH2023
0
0
3
RT @ActImmuno: A New Hope: India's First Approved CAR-T Cell Therapy - No Longer Sci-Fi, Now a Reality!. We are pleased to announce the rec….
linkedin.com
A New Hope: India's First Approved CAR-T Cell Therapy - No Longer Sci-Fi, Now a Reality! We are pleased to announce the receipt of a Marketing Authorization Approval from the CDSCO for NexCAR19...
0
135
0
